articleThe LancetApr 1, 2022BRONZE OA

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Duke University · Clinical Research Institute · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

No related works found for this paper.

Funding